Mycobacterium Infections Treatment Market are a class of multisystem infections caused by a pathogen called mycobacteriaceae. Mycobacterial infections are largely asymptomatic in nature, however, as per the strain and body composition the effects are fatal and can propel hospitalizations in those with the compromised immune system. However, some of the pre-approved medicines utilized for treating the condition are clarithromycin, azithromycin and rifampin, amongst others. Additionally, research and development activities partaken by key players along with climate change subjugating the cases of bacterial spread will allow the Market to grow at a CAGR of 5.6% during the forecast period of 2022-2027, to garner a market size equivalent to $20.2 billion by 2027.

Mycobacterium Infection Treatment Drivers

A Substantial Presence of Tuberculosis Cases across Developing Countries along with Effective Treatment Propositions in Developed Nations have Proliferated the Market Demand.

As per the WHO, nearly 95% of TB cases and deaths occur in developing countries. Moreover, the substantial presence of HIV cases in countries and regions such as Africa has propelled the market demand, as people who are infected with HIV are 18 times more likely to develop active TB. People with undernutrition are 3 times more at risk. Globally in 2020, there were 1.9 million new TB cases that were attributable to undernutrition. Additionally, owing to advanced healthcare systems in developed countries, the detection and correct treatment has proliferated the market demand.

For More Queries About "Mycobacterium Infection Treatment Market" :

A Robust Growth in the Prevalence of NTM along with Strong Research and Development Activities Monitored by Agency such as the WHO has Proliferated Market Demand.

The number of patients treated with NTM diseases worldwide has risen dramatically over the past three decades. Recent estimates from Breathe 2022, suggest an incidence of up to 14.1 cases per 100,000 worldwide, thereby curating positive affluence over the treatments market. Critically, research highlights a strong correlation between the incidence of NTM and climate change, leading to an increased Tropics area. Lastly, strong monitoring of prepositions by the WHO has aided in the strong market growth in the market.

Clinical Trial and Product Approval

In October 202, Microbion Corporation announced the positive effects of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species. In September 2022, FDA approved Oxford Immunotec’s T-Cell Select Reagent Kit to automate the workflow of T-Sport TB.

Major Players in the Market Include

The Major Players in the Mycobacterium Infections Treatment Market Include Insmed Incorporated, Red Hill Biopharma, Novartis, Savara, Beyond Air, Sanofi, Novartis AG, CMP Pharma and Cipla.

Over the years, key company focus has shifted to finding alternative treatment ways for tackling the growing cases of multidrug-resistant TB amongst other priorities for clinical research.

To request for a quote, provide your details in the below link:

Media Contact:

Mr. Venkat Reddy
Sales Manager
Contact Sales: +1-970-236-3677

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.